Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
2.
Peptides ; 119: 170117, 2019 09.
Artigo em Inglês | MEDLINE | ID: mdl-31276730

RESUMO

Lipocalin-2 (LCN-2), a peptide with diverse expression pattern, has been identified as a biomarker of various diseases as well as a factor contributing to inflammatory responses associated with excess adiposity and ensuing metabolic disorders. Although the inter-relationship between LCN-2 and excess adiposity is increasingly recognized, little is known about the inter-relationship between LCN-2 and ectopic fat deposition. The present study aimed to investigate the associations between LCN-2 and fatty pancreas as well as fatty liver. In addition, the associations between LCN-2 and pro-inflammatory cytokines were studied. Magnetic resonance imaging was used to quantify intra-pancreatic fat deposition and visceral-to-subcutaneous fat volume ratio whereas magnetic resonance spectroscopy was used to quantify liver fat deposition. Fasting venous blood was analyzed for LCN-2, C-C motif chemokine ligand 2, interleukin-6, leptin, tumor necrosis factor-α, glycated hemoglobin, glucose, and insulin. Binary logistic regression and linear regression analyses were conducted. Three statistical models were built to adjust for demographics, comorbidities, levels of glycated hemoglobin, insulin resistance, and abdominal fat distribution. A total of 79 individuals were studied, of whom 20 had fatty pancreas, 14 had fatty liver, and 4 had both. Lipocalin-2 was significantly associated with fatty pancreas in all the adjusted models (p = 0.014 in the most adjusted model) but was not significantly associated with fatty liver in any of the studied models. Lipocalin-2 was significantly associated with interleukin-6 and tumor necrosis factor-α, in both the unadjusted and adjusted models. Leptin and C-C motif chemokine ligand 2 were not significantly associated with LCN-2 in any of the studied models. These findings suggest that LCN-2 is a potential biomarker of fatty pancreas, independent of abdominal fat distribution, insulin resistance, and other covariates. The role of LCN-2 in intra-pancreatic fat deposition and related low-grade inflammation warrants further investigations.


Assuntos
Lipocalina-2/sangue , Pancreatopatias/sangue , Adulto , Idoso , Quimiocina CCL2/sangue , Estudos Transversais , Fígado Gorduroso/sangue , Feminino , Humanos , Interleucina-6/sangue , Masculino , Pessoa de Meia-Idade , Fator de Necrose Tumoral alfa/sangue
3.
J Clin Med Res ; 11(6): 435-446, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-31143311

RESUMO

BACKGROUND: Conventional anthropometric indices (body mass index (BMI) and waist circumference (WC)) have limitations, in part, due to ethnic differences in fat distribution. Assessment of abdominal body composition using magnetic resonance imaging (MRI) is increasingly used to gain deeper insights into the pathophysiology of diabetes mellitus, cardiovascular diseases and metabolic syndrome, but the knowledge of abdominal volumes in indigenous populations is scarce. This study aimed to assess abdominal fat distribution and total abdominal volume using MRI in a multi-ethnic cohort that includes Maori (the indigenous people of New Zealand) and Pacific Islanders (PI). METHODS: MRI was used to quantify subcutaneous adipose tissue (SAT) volume, visceral adipose tissue (VAT) volume and total abdominal (TAb) volume by two independent raters in a blinded fashion. WC and BMI were also measured. Multinomial regression was used to compare the volumes between ethnic groups. Linear regression was used to investigate the ethnicity-specific associations between anthropometric indices and abdominal volumes. Three statistical models were built to adjust for age, sex, prediabetes/diabetes status and other covariates. RESULTS: A total of 87 individuals (37 Caucasians, 24 Maori/PI and 26 others) were studied. Maori/PI had a significantly higher VAT volume compared with Caucasians across all statistical models, with the highest odds ratio of 2.1 (95% confidence interval: 1.1 - 4.2; P = 0.026). SAT and TAb volumes did not differ significantly between the groups. WC explained up to 72.9% of variance in VAT volume among Maori/PI and up to 50.7% among Caucasians. BMI explained up to 67.6% of variance in VAT volume among Maori/PI and up to 52.1% among Caucasians. CONCLUSIONS: Greater visceral fat deposition among Maori/PI might go some way towards explaining the increased rates of metabolic disorders observed in this ethnic group. Conventional anthropometric indices do not correspond to the same abdominal volumes across different ethnic groups.

4.
J Clin Exp Hepatol ; 9(2): 171-175, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31024198

RESUMO

BACKGROUND AND AIMS: Understanding of the significant genetic risk factors for Cholangiocarcinoma (CC) remains limited. Polymorphisms in the natural killer cell receptor G2D (NKG2D) gene have been shown to increase risk of CC transformation in patients with Primary Sclerosing Cholangitis (PSC). We present a validation study of NKG2D polymorphisms in CC patients without PSC. METHODS: Seven common Single Nucleotide Polymorphisms (SNPs) of the NKG2D gene were genotyped in 164 non-PSC related CC subjects and 257 controls with HaploView. The two SNPs that were positively identified in the previous Scandinavian study, rs11053781 and rs2617167, were included. RESULTS: The seven genotyped SNPs were not associated with risk of CC. Furthermore, haplotype analysis revealed that there was no evidence to suggest that any haplotype differs in frequency between cases and controls (P > 0.1). CONCLUSION: The common genetic variation in NKG2D does not correlate significantly with sporadic CC risk. This is in contrast to the previous positive findings in the Scandinavian study with PSC-patients. The failure to reproduce the association may reflect an important difference between the pathogenesis of sporadic CC and that of PSC-related CC. Given that genetic susceptibility is likely to be multifaceted and complex, further validation studies that include both sporadic and PSC-related CC are required.

5.
J Viral Hepat ; 26(6): 750-756, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-30712273

RESUMO

Blood transfusion is one of the most commonly relied upon therapies in sub-Saharan Africa. Existing safeguards recommended include systematic screening for transfusion-transmitted infections and restricted voluntary nonremunerated blood donor selection. We report the transfusion-transmitted infection screening and notification practice at a large urban blood transfusion centre in Dar-es-Salaam, Tanzania. Between October 2016 and March 2017 anonymized records of all donors registered at the blood transfusion unit were accessed to retrospectively note demographic information, donor status, first-time status, transfusion-transmitted infection result and notification. 6402 consecutive donors were screened for transfusion-transmitted infections; the majority were family/replacement blood donors (88.0%) and male (83.8%). Overall transfusion-transmitted infections prevalence was 8.4% (95% CI 7.8-9.1), with hepatitis B being the most prevalent infection (4.1% (95% CI 3.6-4.6)). Transfusion-transmitted infections were more common in family/replacement blood donors (9.0% (95% CI 8.3-9.8)) as compared to voluntary nonremunerated blood donor (4.1% (95% CI 2.8-5.7)). A minority of infected-donors were notified of a positive result (8.5% (95% CI 6.3-11.2)). Although transfusion-transmitted infections are more prevalent among family/replacement blood donors, overall risk of transfusion-transmitted infections across all groups is considerable. In addition, existing efforts to notify donors of a positive transfusion-transmitted infection are poor. Future policies must focus on improving linkage to care for newly diagnosed patients with transfusion-transmitted infections.


Assuntos
Doadores de Sangue , Infecções por HIV/epidemiologia , Hepatite B/epidemiologia , Hepatite C/epidemiologia , Reação Transfusional/epidemiologia , Reação Transfusional/prevenção & controle , Adolescente , Adulto , Transfusão de Sangue , Notificação de Doenças , Família , Feminino , Infecções por HIV/sangue , Infecções por HIV/diagnóstico , Hepatite B/sangue , Hepatite B/diagnóstico , Hepatite C/sangue , Hepatite C/diagnóstico , Humanos , Masculino , Programas de Rastreamento , Pessoa de Meia-Idade , Prevalência , Estudos Retrospectivos , Fatores de Risco , Tanzânia/epidemiologia , Reação Transfusional/virologia , Adulto Jovem
6.
J Clin Exp Hepatol ; 9(6): 740-748, 2019.
Artigo em Inglês | MEDLINE | ID: mdl-31889756

RESUMO

BACKGROUND: Intrahepatic cholangiocarcinoma (iCCA) is usually a fatal malignancy with rising incidence globally. Surgical resection currently remains the only curative treatment. However, as only a minority of iCCA is amenable to resection, new therapeutic modalities are needed. Our aims were to systematically review and perform a meta-analysis on the existing literature regarding the use of ablative therapies for iCCA and to assess their efficacy as a treatment modality by calculating pooled survival results and investigate associations between prognostic factors and survival. METHODS: A comprehensive search of the PubMed database for relevant articles was performed. Studies assessing survival in patients with iCCA undergoing ablation were included. Data were extracted on patient, tumour and treatment characteristics and survival. Random effects meta-analysis was used to pool the data. Galbraith plots were used to investigate heterogeneity; bubble plots were formulated using regression-based meta-analysis. RESULTS: A total of 10 studies were included in the final analysis, yielding an aggregate of 206 patients (69.5% males, median age: 51.2-72.5) and 320 tumours. Of all patients, 70.4% were recurrent cases of iCCA, and 29.6% were cases of primary iCCA. The median overall survival ranged from 8.7 to 52.4 months. Pooled 1-, 3- and 5-year survival rates were 76% (95% confidence interval: 68-83%), 33% (21-44%) and 16% (7-26%), respectively. No significant association was found between the median age, number of tumours or median tumour size and 1-year survival. CONCLUSIONS: Ablative therapies display promising potential as treatment modalities for iCCA. However, further research is necessary to validate these findings.

7.
J Viral Hepat ; 25(12): 1438-1445, 2018 12.
Artigo em Inglês | MEDLINE | ID: mdl-29974582

RESUMO

The World Health Organisation has recently called for hepatitis C virus (HCV) elimination and has identified people who inject drugs (PWID) as a key population to scale-up screening and linkage to care. This study reports the cascade of care for HCV in PWID attending the largest opioid substitution treatment (OST) clinic in Dar-es-Salaam, Tanzania. Between February 2011 and March 2016, HCV serology for all PWID registered at the Muhimbili National Hospital OST clinic, Dar-es-Salaam were obtained from records. In 2015, consecutive HCV-seropositive PWID were invited to undergo a clinical evaluation including epidemiological questionnaire, liver stiffness measurement (Fibroscan) and virological analysis (HCV RNA viral load and genotyping). During the study period, 1350 persons registered at the OST clinic: all had a HCV serology including 409 (30%) positive results. Among the HCV-seropositive individuals, 207 (51%) were active attenders and 153 (37%) were enrolled for clinical assessment: 141 (92%) were male, median age: 38 years (IQR 34-41), and 65 (44%) were co-infected with HIV; 116 patients (76%) had detectable HCV RNA, with genotypes 1a (68%) and 4a (32%); 21 (17%) had clinically significant fibrosis (≥F2) and 6 (5%) had cirrhosis (F4). None were offered HCV treatment. Chronic hepatitis C among PWID enrolled in the OST centre in Dar-es-Salaam is frequent, but its continuum of care is insufficient; integration of HCV diagnosis and treatment should form a part of OST intervention in PWID in Tanzania.


Assuntos
Continuidade da Assistência ao Paciente/organização & administração , Gerenciamento Clínico , Hepatite C Crônica/diagnóstico , Hepatite C Crônica/tratamento farmacológico , Abuso de Substâncias por Via Intravenosa/complicações , Adulto , Feminino , Genótipo , Hepacivirus/classificação , Hepacivirus/genética , Hepacivirus/isolamento & purificação , Hepatite C Crônica/epidemiologia , Humanos , Masculino , Programas de Rastreamento/organização & administração , Tanzânia/epidemiologia , Carga Viral
9.
J Clin Exp Hepatol ; 6(3): 186-194, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27746614

RESUMO

BACKGROUND: Discriminatory metabolic profiles have been described in urinary 1H nuclear magnetic resonance (NMR) spectroscopy studies of African patients with hepatocellular carcinoma (HCC). This study aimed to assess similarities in a UK cohort, where there is a greater etiological diversity. METHODS: Urine from cirrhosis and HCC patients was analyzed using a 600 MHz 1H NMR system. Multivariate analysis and median group MR spectra comparison identified metabolite alterations between groups. Metabolite identification was achieved through literature reference and statistical total correlation spectroscopy. Diagnostic accuracy was compared to serum alpha-fetoprotein (AFP). RESULTS: Of the 52 patients recruited, 13 samples from HCC and 25 from cirrhosis patients were selected. At 200 IU mL-1, diagnostic sensitivity of AFP was 27%. Multivariate analysis of urinary spectra generated diagnostic models with a sensitivity/specificity of 53.6%/96%. p-Cresol sulfate (P = 0.04), creatinine (P = 0.03), citrate (P = 0.21) and hippurate (P = 0.52) were reduced in the HCC patients. Carnitine (P = 0.31) and formate (P = 0.44) were elevated. CONCLUSION: Diagnostic sensitivity was lower than previous African studies, but still outperformed serum AFP. Reduced creatinine, citrate and hippurate and elevated carnitine are comparable with the African studies. p-Cresol sulfate alteration is a novel finding and may indicate an altered sulfonation capacity of the liver in patients with HCC.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...